Project Grant R43DA059524

Award Date 9/15/23
Completion Date 9/14/24
Dollars Obligated $320K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding research by Iontx Inc. to advance FGF13-NAV1.6 modulators as a potential treatment for cocaine use disorder (CUD). The $400,000 award supports a 12-month effort to conduct structure-activity relationship (SAR) analysis and optimization of a lead compound (5788), followed by pharmacokinetic studies and in vivo efficacy testing in a rat CUD...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $405,230.00 to Rafias LLC located in Philadelphia, PA. The funding supports research to advance NR4A1 as a novel target for treating cocaine use disorder. Key objectives include: 1) Lead identification by synthesizing and screening CsnB derivatives that activate human/mouse NR4A1, and 2) Lead optimization by characterizing lead compound(s) using...
This $149,284 Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) to Vanderbilt University will fund research to understand how chronic cocaine use disrupts the neural processing of aversive, non-drug stimuli in the brain. The study aims to define the precise temporal parameters under which dopamine release modulates the activity of genetically-defined neuron populations in the nucleus accumbens, both at baseline and in...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $118,656 to the Ponce Medical School Foundation Inc. in Puerto Rico. The funding will support research to investigate the influence of fear conditioning and cocaine exposure on cocaine-seeking behavior in adult rats, with a focus on analyzing the neurophysiological changes in the prelimbic cortex-nucleus accumbens core circuitry. The project aims...
The National Institute on Drug Abuse (NIDA) awarded a $1,585,991 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Icahn School of Medicine at Mount Sinai in New York. The grant, awarded on May 1, 2025, will fund a double-blind randomized trial to evaluate the use of transcranial direct current stimulation (tDCS) combined with cognitive reappraisal training to reduce craving and cue-reactivity in individuals with cocaine use disorder. The study aims to explore...
This Project Grant award, valued at $695,250.00 and awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to investigate the role of endothelial injury and myeloid cell migration in the activation of inflammasomes in HIV infection and cocaine exposure. The key objectives are to characterize myeloid cell populations in the brains of HIV-transgenic mice under chronic cocaine treatment, and evaluate the...
The National Institute on Drug Abuse (NIDA) has awarded a $492,000 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to the University of Chicago to conduct a multidimensional study on the genetic and epigenetic factors underlying cocaine addiction. The 5-year project aims to: Perform high-resolution chromatin accessibility and DNA methylation profiling to delineate cell-type and circuit-specific epigenetic changes following cocaine self-administration in mice. This will...
This federal Project Grant award for $263,119 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) is focused on developing NLRP3 inhibitors to address HIV-associated neuroinflammation in cocaine use. The key objectives are to computationally design, synthesize, and screen novel analogues of a lead compound, AMS-17, to improve its biological activity and maintain low toxicity. The project involves in vitro and in vivo screening of...
This Project Grant award, with Federal Grant ID R21DA060442, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $234,000 award supports research to understand the mechanisms underlying cue-induced cocaine craving, a core feature of substance use disorder. The key objectives are to: 1) Use translating ribosome affinity purification and RNA-sequencing (TRAP-SEQ) to identify mRNAs actively translating in nucleus...
This Project Grant award of $1,447,919.00 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research on cocaine addiction and the "need-state hypothesis" at Pennsylvania State University's Milton S. Hershey Medical Center. The research aims to use an animal model to identify individual vulnerability to cocaine addiction early in the disease state, and explore the use of a known satiety agent, glucagon-like...

This $319,547 project grant awarded on September 15, 2023 by the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279) supports Afasci, Inc.'s research and development of a novel treatment for cocaine use disorder (CUD). The project will investigate the effects of Afasci's investigational new drug AFA-281, which inhibits both the T-type Cav3 ion channels and soluble epoxide hydrolase, on reducing cocaine-seeking behavior and hyperlocomotion in preclinical rat models. Success in this SBIR Phase I project will demonstrate proof of concept, potentially leading to further clinical development of AFA-281 for CUD through a Phase II project or with third-party support. The goal is to develop a safe, effective, and accessible medication to mitigate the impact of CUD.

Generated 7/16/24, 9:46 AM